Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer
Combining RAI therapy with lenvatinib improved ORR with clinically meaningful prolongation of PFS; however, it comes with a burden of treatment-related toxicity, underscoring the need for careful patient selection.
Authors
- Chandra Teja Reddy Singareddy (ORCID: https://orcid.org/0000-0003-3264-9579)
- Swayamjeet Satapathy (ORCID: https://orcid.org/0000-0001-5318-6644)
- Madhavi Tripathi (ORCID: https://orcid.org/0000-0003-1033-1690)
- Chandrasekhar Bal
- Kunal Ramesh Chandekar (ORCID: https://orcid.org/0009-0007-3599-0322)
- Ranjit Kumar Sahoo (ORCID: https://orcid.org/0000-0002-4130-724X)
- Sanjana Ballal
Institutions
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1097/rlu.0000000000006146
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00